Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.

Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K.

J Immunother. 2012 Jul;35(6):460-72. doi: 10.1097/CJI.0b013e31826092db.

PMID:
22735804
2.
3.

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.

Clin Immunol. 2007 Oct;125(1):76-87. Epub 2007 Aug 13.

PMID:
17706463
4.

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, Chen L, Friedl P, Melero I.

Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1.

5.

Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.

Ju SA, Lee SC, Kwon TH, Heo SK, Park SM, Paek HN, Suh JH, Cho HR, Kwon B, Kwon BS, Kim BS.

Immunol Cell Biol. 2005 Aug;83(4):344-51.

PMID:
16033529
6.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

7.

Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.

Ju SA, Park SM, Lee SC, Kwon BS, Kim BS.

Mol Cells. 2007 Aug 31;24(1):132-8.

8.

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, Ochoa-Callejero L, Martínez A, Luque A, Dinchuk J, Rouzaut A, Jure-Kunkel M, Melero I.

Cancer Res. 2011 Feb 1;71(3):801-11. doi: 10.1158/0008-5472.CAN-10-1733. Epub 2011 Jan 25.

9.

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.

Murillo O, Dubrot J, Palazón A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, Pérez-Gracia JL, Berraondo P, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2009 Sep;39(9):2424-36. doi: 10.1002/eji.200838958.

10.

Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells.

Shao H, Fu Y, Liao T, Peng Y, Chen L, Kaplan HJ, Sun D.

Invest Ophthalmol Vis Sci. 2005 Feb;46(2):596-603.

PMID:
15671287
11.

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.

PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.

12.

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.

J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.

14.

Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.

Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ.

J Immunol. 2010 May 15;184(10):5493-501. doi: 10.4049/jimmunol.0903033. Epub 2010 Apr 16.

15.

In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.

Teschner D, Wenzel G, Distler E, Schnürer E, Theobald M, Neurauter AA, Schjetne K, Herr W.

Scand J Immunol. 2011 Aug;74(2):155-64. doi: 10.1111/j.1365-3083.2011.02564.x.

16.

Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.

Kurosawa S, Harada M, Matsuzaki G, Shinomiya Y, Terao H, Kobayashi N, Nomoto K.

Immunology. 1995 Jun;85(2):338-46.

17.

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.

Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I.

Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19.

18.

Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.

Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Canè S, Pecorelli S.

Gynecol Oncol. 2003 May;89(2):271-80.

PMID:
12713991
19.

Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites.

Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee SY, Kwon B.

Cancer Lett. 2013 Apr 28;330(2):190-9. doi: 10.1016/j.canlet.2012.11.045. Epub 2012 Dec 3.

PMID:
23219755
20.

Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.

Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, Yokoyama WM, Kim TY, Kwon BS.

Cancer Res. 2007 Sep 15;67(18):8891-9.

Supplemental Content

Support Center